Bajpai J, Ramaswamy A, Gupta S, Ghosh J, Gulia S
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India.
Indian J Cancer. 2016 Jul-Sep;53(3):460-463. doi: 10.4103/0019-509X.200653.
Heavily pretreated metastatic breast cancer (MBC) remains a major therapeutic challenge with limited treatment options this. Eribulin, an anti-microtubule agent, has been recently approved for this indication. There are sparse data from the Asian region for eribulin and merits exploration.
This was a single institution retrospective analysis of MBC patients treated with eribulin from 2013 to 2014. These patients had received at least 2 lines of prior therapy for metastatic disease. Patients received standard doses of eribulin and were monitored for toxicity and responses.
Eighteen patients were included in this analysis. They had received a median of 6 lines of therapy previously (including adjuvant treatment) and had significant visceral involvement (median 3 organs). A median of 4 cycles of eribulin was delivered. There were no complete responses; partial responses were seen in 33% (6/18), stable disease status in 28% (5/18) patients, and progressive disease on eribulin in 39% (7/18) patients. The median progression-free survival was 15 weeks (3.5 months), and median overall survival was 27 weeks (6.2 months). Significant Grade 3/4 toxicities seen included peripheral neuropathy in 28% (5/18) and neutropenia in 28% (5/18) of patients while dose reductions were required in 22% (4/18) of patients.
Eribulin offers a viable, well-tolerated regimen that provides meaningful clinical benefit in Indian patients with MBC.
经过大量前期治疗的转移性乳腺癌（MBC）仍然是一个重大的治疗挑战，可供选择的治疗方案有限。艾日布林是一种抗微管药物，最近已被批准用于这一适应症。亚洲地区关于艾日布林的数据稀少，值得探索。
这是一项对2013年至2014年接受艾日布林治疗的MBC患者进行的单机构回顾性分析。这些患者此前至少接受过2线转移性疾病的治疗。患者接受标准剂量的艾日布林治疗，并监测毒性和反应。
本分析纳入了18例患者。他们此前接受的治疗中位数为6线（包括辅助治疗），并有明显的内脏受累（中位数为3个器官）。艾日布林的给药中位数为4个周期。没有完全缓解；33%（6/18）的患者出现部分缓解，28%（5/18）的患者疾病稳定，39%（7/18）的患者在接受艾日布林治疗后疾病进展。无进展生存期的中位数为15周（3.5个月），总生存期的中位数为27周（6.2个月）。观察到的3/4级显著毒性包括28%（5/18）的患者出现周围神经病变，28%（5/18）的患者出现中性粒细胞减少，22%（4/18）的患者需要减少剂量。
艾日布林提供了一种可行的、耐受性良好的治疗方案，对印度MBC患者具有显著的临床益处。
